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Abstract The CCN family of proteins (CCN1, CCN2,
CCN3, CCN4, CCN5 and CCN6) are multifunctional
mosaic proteins that play keys roles in crucial areas of
physiology such as angiogenesis, skeletal development
tumourigenesis, cell proliferation, adhesion and survival.
This expansive repertoire of functions comes through a
modular structure of 4 discrete domains that act both
independently and in concert. How these interactions with
ligands and with neighbouring domains lead to the
biological effects is still to be explored but the molecular
structure of the domains is likely to play an important role
in this. In this review we have highlighted some of the key
features of the individual domains of CCN family of
proteins based on their biological effects using a homology
modelling approach.
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Introduction
The CCN family of proteins is a crucial group of signalling
molecules found in eukaryotic organisms. The CCN
nomenclature is due to the first three and most well studied
members of the family: Cyr61 (Cysteine rich protein 61),
CTGF (Connective tissue growth factor) and NOV (Neph-
roblastoma overexpressed gene) (Bork 1993) which are
now designated CCN1, CCN2 and CCN3 (Brigstock et al.
2003). Three other family members (CCN4/WISP1, CCN5/
WISP2 and CCN6/WISP3) have been described. Each of
the CCN molecules was given several other names relating
to other biological activities that they possess based on the
wide range of biological functions they are involved in
including- adhesion, mitogenesis, migration and chemotaxis,
cell survival, differentiation, angiogenesis, chondrogenesis,
tumourigenesis and wound healing making them an impor-
tant group of molecules to study (Brigstock et al. 2003).
The full scope of the CCN proteins’ biological function
is beyond the scope of this article but details can be found
in a wide range of reviews (Lau and Lam 1999; Brigstock
1999; Perbal 2001a; Perbal 2004; Perbal and Takigawa
2005; Leask and Abraham 2006).
The multi-domain structure of the CCN proteins
Like many extracellular matrix (ECM) proteins the CCN
family of proteins (Table 1) is constructed from a series of
discrete domains built from the library of known eukaryotic
domains (Hohenester and Engel 2002). The domains in the
CCN molecules have been identified through sequence
alignment or conserved amino acid motifs (Bork 1993)
although the exact biological role of each module is still not
fully understood. We have constructed structural models of
each of the individual domains and tried to correlate them
with the known functional aspects of each domain.
The CCN proteins all share the same modular structure
of 4 well ordered and discrete domains that are stable as
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small truncates or individually (Kubota et al. 2006) and are
closely related on the amino acid level with ~30–50%
identity (40–60% similarity) (Brigstock et al. 2003; Perbal
and Planque 2006; Kubota and Takigawa 2006; Schuetze et
al. 2006). The protein is threaded in 4 domains at both
protein and DNA levels with an exon corresponding to the
signal sequence followed by 4 more exons, one per domain.
Many large multi-modular human proteins are built in this
way from blocks of exons and it is thought that many
mosaic extracellular proteins have come about through
evolutionary shuffling of these basic building blocks (Bork
1993; Bornstein 1995; Kireeva et al. 1996). A sequence
alignment of the CCN proteins using the T-Coffee program
(Notredame et al. 2000) highlighting the conserved cysteine
residues and other notable parts of each domain is shown
below in Fig. 1 (Holbourn et al. 2008). In the CCN proteins
the domain following an N-terminal secretory signal
peptide are: (i) An insulin-like growth factor binding
protein —like domain (IGFBP), (ii) A von Willebrand
factor type C repeat module (VWC), (iii) A Thrombospon-
din type-1 repeat module (TSP1) and (iv) A Cysteine knot
containing module (CT). A representation of each domain
and their known binding partners are shown in Fig. 2 (Bork
1993). CCN5 is the exception to this arrangement as it
lacks the 4th CT domain. Another notable feature of the
CCN proteins is their high cysteine content, almost 10% by
mass that includes 38 cysteines divided into 17 potential
conserved disulphide bonds spread across the 4 domains,
except CCN5 that lacks 10 cysteines in its missing CT
domain and CCN6 that lacks 4 cysteines in the VWC
domain. The entire molecule can also be split into two
halves, an N-terminal half with the IGFBP and VWC
domains and the C-terminal half with the TSP and CT
domains, separated by a flexible and protease vulnerable
linker (Bork 1993; Lau and Lam 1999). This linker region
while varying greatly in length and amino acid composition
does have several “L/I/Y R/V” sites that are vulnerable to
proteolysis by a selection of matrix metalloproteases
(MMPs) (Hashimoto et al. 2002). It has been shown that
a wide variety of matrix metalloproteases (MMP-1, 2, 3, 7,
9 ,13) target this central linker region and additional
proteases such as elastase and plasmin could attack linkers
that connect domains 1 and 2 or domains 3 and 4 (de
Winter et al. 2008; Hashimoto et al. 2002; Brigstock et al.
1997; Ball et al. 1998). Cleavage at these sites can give




CCN1 Cyr61, CTGF-2, IGFBP10, IGFBP-rP4
CCN2 CTGF, IGFBP8, IGFBP-rP2, HBGF-0.8 ecogenin
CCN3 NOV, NOVH, IGFBP9, IGFBP-rP3
CCN4 Wisp-1, Elm-1
CCN5 Wisp-2, CTGF-L, CTGF-3, HICP, Cop-1
CCN6 Wisp-3
Fig. 1 Sequence alignment of the CCN proteins. The sequences of
the 6 human CCN proteins were aligned using the T-Coffee server
(Notredame et al 2000). The start and finish points of each domain are
indicated and various important regions on the molecules are
highlighted. In the IGFBP domain the “thumb” and GCGCCxxC
motif are shaded in red. In the VWC domain the integrin αvβ3 site is
highlighted in yellow. In the TSP domain the α6β1 binding site is
highlighted in blue. This region also contains the bioactive peptide
section (Karagiannis and Popel 2007). The integrin α6β1 and HSPG
binding sites and the possible reverse integrin GDR motif in the CT
domain are all highlighted in green
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bioactive truncated components that can be used as markers
in some types of disease including some fibrotic diseases
(N-terminal fragments) (Gao and Brigstock 2004) and some
types of pancreatic cancer (C-terminal fragments) (Gao and
Brigstock 2006). These truncated components can show
distinct biological properties and might constitute an
additional process for the regulation of the biological
activity of the CCN proteins and in some cases to be
associated with some of their functions (Perbal 2001b;
Perbal 2004; Tong and Brigstock 2006; Brigstock 1999).
Whilst each module no doubt has its own specific
biological role many of the functional effects of the CCN
family come about through multiple modules acting in
concert. Truncated proteins, or proteins missing internal
modules, have been shown to possess different biological
activities, and in some cases be associated to pathological
situations (Perbal 2001b). An example of the multi-domain
requirements of some functions has been seen in CCN2
where individual modules could replicate some of the
effects of full length CCN2 but for other functions, such as
p38 MAPK activation the full length protein or a cocktail
containing the 4 individual domains was required (Kubota
et al. 2006). The ability of the 4 individual modules to give
rise to the same biological behaviour as the full length
protein suggest that there must be some sort of cumulative
physical interaction between multiple modules and the
substrates.
The IGFBP domain
There are 6 members in the human insulin-like growth
factor binding protein (IGFBP) family and they are
involved in several important biological functions that are
centred around modulating insulin-like growth factors
(IGFs): 1) to act as a transport proteins for the IGFs, 2) to
enable localisation of IGF availability, 3) to regulate the
metabolic break down of IGFs and extend their biological
lifespan and 4) to directly affect the interaction between
IGFs and their receptors on the cell surface and in doing so
indirectly control IGF function (Jones and Clemmons
1995). The indirect control of IGF function extends the
role of the IGFBP proteins into many diverse areas of
cellular functions including: amino acid and glucose
uptake, cell cycle progression, cell proliferation; cell death,
cell differentiation; chemotaxis, hormone and neurotrans-
mitter secretion, and parts of the immune response (Jones
and Clemmons 1995). Recently modulation of IGF function
was shown to play a critical role in aggressive inflamma-
tory breast cancers and in a wide variety of other cancers
(Helle 2004). The strong link between IGF regulation and
cancer could be important for CCN4-6 that are heavily
involved in aggressive inflammatory breast cancer and
exert their influence via control and manipulation of IGF-1
(Zhang et al. 2005; Davies et al 2007). Whether this
interaction is as a result of the IGFBP domains of CCN4-6
Fig. 2 Details of the individual domains . Close-up views of each of
the domains using the model domains of CCN1. The known substrates
for each domain are listed including: insulin like growth factors
(IGFs); bone morphogenic proteins (BMPs); transforming growth
factor –β (TGF); LDL receptor protein 1 (LRP1) and heparin
sulphated proteoglycans (HSPGs). In the IGFBP domain the two
subdomains can be seen and the ladder of disulphide bonds in the
“palm” sub-domain. In the VWC domain the two sub-domains can be
seen; the more structured N-terminal domain and the less structured C-
terminal domain in a fibronectin like fold. In the TSP domain the 3
strands are visible and the CWR layers are labelled. In the partial
model of the CT domain the cysteine knot can be seen although the
heparin binding N-terminal tips cannot be seen. An unbound cysteine
protrudes through the centre of each knot though it is unknown if this
is used to form dimers or a disulphide bridge with another cysteine in
the missing (not modelled) section of the CT domain
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interacting directly with IGF or indirectly through other path-
ways is unknown.
The IGFBP have several distinguishing features in
addition to a strong sequence similarity and conserved
motifs. They are cysteine rich bi-domain proteins with their
N- and C-terminal domains linked by a short flexible
region. The linker region varies between IGFBPs and
similar to the inter-domain linkers in the CCN family and
has several sites vulnerable to protease degradation (Hwa et
al. 1999; Firth and Baxter 2002). There are a total of 18
cysteines, 12 in the N-terminal domain and 6 in the C-
terminal domain that are all potentially involved in internal
disulphide bond formation within each domain. The N-
terminal domain is the domain that is found in the CCN
family and is a globular domain that contains one of the
conserved motifs as well as the IGF binding cavity (Kalus
et al. 1998; Hwa et al. 1999). Although the N-terminal
domain contains the IGF binding cavity it is the jaw-like
structure of the N- and C-termini surrounding the IGF
molecule that leads to high affinity (KD ~1nM) binding.
Importantly, it has been reported that the N and C terminal
regions can bind IGF independently in some of the
IGFBPs, as would be the case for the IGFBP domain in
the CCN proteins (Kim et al. 1997) though when working
independently the IGF binding is several orders of
magnitude lower than the full length protein (Stndker et
al. 2000).
The CCN proteins have been classified by some as
additional IGFBPs or as IGFBP-related proteins (IGFBP-
rPs) (Hwa et al. 1999; Kim et al. 1997) due to their high
degree of sequence homology to the N-terminal region of
the traditional IGFBPs. Though the CCN domains’ IGF
affinity is hundred fold lower than the full length IGFBPs it
is in the same range as the binding seen for N-terminal
truncates of the IGFBPs (Kim et al 1997; Yamanaka et al.
1997). The reduced IGF affinity, due to the lack of a C-
terminal domain in CCN proteins has led to two classes of
IGFPBs; high and low affinity IGFBPs. In this classifica-
tion, the 6 traditional IGFBPs are considered high affinity
and the CCN proteins (IGFBP-rPs) and other proteins that
only contain an N-terminal IGFPB domain are considered
low affinity binders (Hwa et al 1999; Kim et al 1997).
In the CCN family there is little information on the exact
role played by the IGFBP domain in CCN function. The
binding of CCN domains to IGF is still not fully
characterised as in some experiments IGF binding by
CCN IGFBP domain has been found to be lacking and
chimeras with the C-terminal domain of IGFBP3 fused to
the IGFBP domain of CCN3 have shown lack of binding
(Yan et al. 2006). Although its binding and interactions
with IGF are for the most part unknown and subject to
considerable debate, it has been shown that the independent
IGFBP domain is biologically active in other cellular
pathways (Kubota et al. 2006). The IGFBP domain of
CCN2 is capable of stimulating JNK mediated prolifera-
tion, in contrast to the other domains promoting differen-
tiation, and it is the only independent domain that was
unable to promote ERK signalling (Kubota et al. 2006). In
healthy cells the IGFBP domain of CCN6 is thought to be
involved in regulating IGF-1 availability (Perbal 2003;
Zhang et al. 2005). This IGF regulation may prove to be
important in cancer as IGF is a key regulatory molecule and
its deregulation can lead to several types of severe cancer
(Zhang et al. 2005; Davies et al. 2007). CCN6 has been
seen to be knocked out in 80% of cases of aggressive
inflammatory breast cancer and results in uncontrolled
IGF1 induced cell growth and tumourigenesis. Functional
CCN6 has been seen to limit the invasive and motile effects
of unregulated IGF that can lead to aggressive inflamma-
tory breast cancer (Zhang et al. 2005) though the exact
mode through which it inhibits tumour growth is unknown.
This role in breast cancer mediated through IGF function is
shared to a lesser extent with CCN4 and 5 (Zhang et al.
2005). In addition CCN4–6 can now be used as prognostic
markers for breast and other cancer leading suggesting the
IGFBP domain plays an important, and as yet not fully
understood role in tumourigenesis (Davies et al. 2007).
The CPH model server (Lund et al. 2002) was used to
construct models of the IGFBP domains of CCN1, 2, 3 and
6, which are shown in Figs. 3, 4, 5 and 6, using the 79
amino acid NMR structure of IGFBP4 as the template with
which they share ~30% sequence identity [PDB code 1dsp]
(Sitar et al. 2006) and a high level of similarity. The struc-
ture of IGFBP4 N-terminal has a roughly L-shaped ap-
pearance and can be divided into two perpendicular
subdomains connected by a short stretch of coil and has
been compared to a hand with a “palm”, “thumb” and
“finger” sections. The first of these subdomains consists of
a 2-stranded β-sheet adjacent to a ladder of parallel loops of
coil stabilised by 3 disulphide bonds that are in the same
plane forming the flat palm of the molecule and can be seen
in Fig. 2. This is a structural segment of the domain as it is
not involved in IGF binding (Kalus et al 1998; Sitar et al.
2006). In some of the traditional IGFBPs such as IGFBP4
(Sitar et al. 2006) the very N-terminal residues protrude
forming a “thumb” on the IGFBP binding domain that can
play a role in binding to the IGFs by wrapping around the
IGF molecule and forming hydrophobic interactions with
aromatic residues of the IGF molecule to increase the
affinity (Sitar et al. 2006). However these thumb segments
are not seen in sequence alignments with the CCN IGFBP
domains. The second subdomain, forms the “fingers” of the
N-terminal domain, is a globular domain centred around a 3
stranded anti-parallel β-sheet strengthened by an internal
disulphide bridge that links strands 1 and 3. The IGF bind-
ing site is formed in this small subdomain forming a cleft
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lined by mainly hydrophobic residues that comfortably
accommodate a large hydrophobic patch on the IGF
molecule (Kalus et al. 1998; Siwanowicz et al. 2005; Sitar
et al. 2006). The strongly conserved GCGCCxxC motif is
not actually involved directly in IGF binding instead being
a structural motif that enables the globular domain to form a
rigid base that supports and separates the thumb sequence
and “fingers” to keep them in correct positions to bind the
IGF molecule (Sitar et al 2006).
The CCN1, 2, 3 and 6 IGFBP domains were successfully
modelled by the CPH model server (Lund et al. 2002),
(Figs. 3, 4, 5 and 6). Poor sequence similarity between the
IGFBP4 template and CCN4 and CCN5 are the likely reason
why the program could not model the domain for all CCN
proteins. Even then, the model of CCN6 is poor missing out
many of the features but this is likely due to it being an
incomplete model rather than any significant biological
difference. The models of CCN1-3 when compared to
IGFBPs maintain the same overall structure with parallel
loops supported by a ladder of 3 disulphide bonds and the
flat palm and globular finger regions flanking the IGF
binding cleft. Despite the high degree of similarity between
the models and the known IGFBP structures there are some
significant differences in key areas, most importantly the
thumb region and the IGF binding cleft. The thumb region is
missing in the CCN family. In the traditional IGFBPs the
thumb has a conserved XhhyC motif (‘h’ is a hydrophobic
amino acid and ‘y’ is positively charged residue) (Kalus et al.
1998; Siwanowicz et al. 2005; Sitar et al. 2006) but as can
be seen in the sequence alignment in Fig. 1 the CCN
molecules have a wide range of different amino acids in this
region. The second difference lies in IGF binding cleft
Fig. 3 Model of CCN1. The
model of the 4 domains of
CCN1 is shown in ribbon and
surface representations arranged
in N- to C- termini from top to
bottom. The linker regions with
their variable sequence and
flexible nature could not be
modelled and it is unknown if
there are intra-domain interac-
tions about a hinge. This figure
was adapted from Holbourn et al
(2008) with permission from the
authors
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which in IGFBP4 and 5 is comprised mainly of hydropho-
bic residues, including in the case of IGFBP5 a short
leucine rich segment (Kalus et al. 1998). In the CCN
proteins this section is a mix of different amino acids
although the effect that this variation has is unknown, but
may go some way to explaining the weak to non-existent
IGF binding displayed by the CCN family. When the
electrostatic surfaces of each molecule are displayed other
differences could be observed. Whist the molecules share
the same overall structure and disulphide bonding patterns
the changes in surface properties may begin to account
for the differences in binding partners and activities be-
tween the members of the CCN family.
The von Willebrand factor C repeat domain
The von Willebrand factor type C (VWC), also known as
the chordin-like cysteine rich (CR) repeat, is found in >500
extracellular matrix proteins making it one of the most
common domains found in the genome (Zhang et al.
2007). The molecules that it can be found in are varied and
include CCN proteins, procollagen, thrombospondin, von
Willebrand factor, glycosylated mucins and neuralins
(Abreu et al. 2002). In many of these proteins there are
multiple copies of the VWC domain. For example the von
Willebrand factor (Mancuso et al. 1989) contains 2 repeats
or chordin that contains 4 repeats (O’Leary et al. 2004).
The CCN proteins are perhaps slightly unusual in that it has
a single copy, and in the case of CCN6 it is an incomplete
copy lacking four of the 10 conserved cysteine residues
(Bork 1993).
Regulation of bone morphogenic proteins (BMPs) and
transforming growth factor beta (TGF-β) are the two most
common functions ascribed to the VWC domain and
common across many proteins it can be found in (Zhu et
al. 1999; Nakayama et al. 2001; Sakuta et al. 2001; Abreu
et al. 2002). Both TGF-β and the BMPs are important
members of a large family of small growth factors such as
TGF-β, Vascular endothelial growth factor (VEGF) and
Placenta growth factor (PlGF). In the case of TGF-β and
the BMPs they are regulating molecules responsible for
Fig. 4 Model of CCN2. The
model of the 4 domains of
CCN2 is shown in ribbon and
surface representations arranged
in N- to C- termini from top to
bottom. The linker regions with
their variable sequence and
flexible nature could not be
modelled and it is unknown if
there are intra-domain interac-
tions about a hinge. Unlike the
others the CT domain of CCN2
has a predicted short α-helix in
place of a β-strand. This figure
was adapted from Holbourn et al
(2008) with permission from the
authors
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organ growth and development for the kidneys, lungs and
teeth as well as in skeletal formation, patterning and
influencing the growth of both bone and cartilage (Hogan
1996a; Hogan 1996b).
The interaction between the CCN proteins and the small
growth factor family is a key one that is responsible for
many of the CCN protein functions and involves both the
VWC and TSP domains. Some important functions that the
CCN-growth factor interactions regular include: TGF-β
mediated adhesion and tissue remodelling (Perbal and
Takigawa 2005), induction of angiogenesis (Lau and Lam
1999), kidney development (Joliot et al. 1992), chondro-
genic and skeletal development (O’Brien and Lau 1992;
Kireeva et al. 1996; Wong et al. 1997) and a host of other
TGF-β related pathways (Brigstock 1999; Lau and Lam
1999; Perbal 2004).
The range of substrate specificity for these growth
factors across the spectrum of VWC domains found in
humans is quite large. In addition, given the many varied
biological functions these repeats have, the differences in
Fig. 5 Model of CCN3. The
model of the 4 domains of
CCN3 is shown in ribbon and
surface representations arranged
in N- to C- termini from top to
bottom. The linker regions with
their variable sequence and
flexible nature could not be
modelled and it is unknown if
there are intra-domain interac-
tions about a hinge. This figure
was adapted from Holbourn et al
(2008) with permission from the
authors
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substrate or relative strengths of binding substrate binding
are likely to play a role in the VWC domain’s biological
role. For example CCN2 binds to BMP4 and TGF- β1,
(Abreu et al. 2002) and CCN3 binds to BMP2 (Minamizato
et al. 2007) whilst chordin binds to BMP-4, −5 and −6 as
well as TGF-β1 and -β2 (Nakayama et al. 2001) despite the
high similarity between the VWC domains. In addition
while CCN2 binds both TGF-β1 and BMP4 it has a higher
affinity for BMP4 (KD 5nM compared with 30nM for TGF-
β1) (Abreu et al. 2002) which may be important for the role
of CCN2 in BMP and TGF-β related functions. In the case
of CCN2 the relatively low affinity for TGF-β1 may
explain CCN2's role as a chaperone of TGF-β1 transferring
it between high affinity receptors with affinities in the
picomolar range (Massague 1987) rather than accentuating
TGF-β1 signalling. By comparison the strong interaction
with BMP4 results in inhibition of BMP4’s activity (Abreu
et al. 2002).
A second major function of the CCN family of proteins
is in modulating the contents of the ECM; and interactions
between the VWC domain and growth factors may hold the
key to this. Several important ECM molecules such as
collagen and fibronectin can be modulated by the CCN
proteins and may take place through induction via TGF-β1
(Roberts et al. 1986; Brigstock 1999; Abreu et al. 2002).
Recently, the physical interaction of CCN3 and BMP2 was
shown to inhibit BMP2-induced osteoblast differentiation
(Minamizato et al. 2007). Interactions between CCN
molecules and growth factors may also play roles in tumour
formation and cell development as with some CCN3
biological mutants lacking the VWC domain being found
in both Wilms tumours and in Ewing’s tumours (Perbal et
al. unpublished results). Similarly CCN4 lacking the VWC
domain has been linked to schirrhous gastric carcinoma
(Tanaka et al 2001).
Lastly, a putative third function for the VWC domain, in
addition to interacting directly with growth factors and
involvement in cancer, for the VWC domain may be in
large scale oligomerisation of CCN molecules. Its is known
that in von Willebrand Factor it is the VWC domain that is
Fig. 6 Models of CCN 4–6. The partial models of CCN4–6 are
shown in ribbon and surface representations arranged in N- to C-
termini from top to bottom. The linker regions with their variable
sequence and flexible nature could not be modelled and it is unknown
if there are intra-domain interactions about a hinge. The question
marks represent domains that were unable to be modelled. The IGFBP
domain of CCN6 shows considerable differences to the CCN1-3
IGFBP domains although this is likely due to incomplete modelling
rather than a biological difference. This figure was adapted from
Holbourn et al (2008) with permission from the authors
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responsible for forming large scale oligomers after a
separate dimerisation step has taken place, and it is possible
that this also be the case in CCN molecules. The CT
domain is well known for its ability to form both homo-
and hetero-dimers of CCN molecules (Perbal et al. 1999)
and if the VWC domain can then make larger oligomers of
homo- and hetero- nature this may add an additional layer
of complexity to CCN regulation (Voorberg et al. 1991;
Brigstock 1999; Perbal 2001b). Another reason for the
oligomerisation may come about through an additive
affinity of multiple VWC domains working in concert. In
chordin and the other multiple copy proteins the affinity for
growth factors varies between repeats and the activity of
intact proteins with multiple VWC domains, can be as
much as 10 fold higher than that for an individual repeat
suggesting a complicated means of regulation (Larrain et al.
2000). The significance of this effect upon the function and
regulatory activity of the single VWC domain in CCN
proteins is not yet known.
The VWC repeat is a short ~70 amino acid stretch
containing 10 cysteine residues that are part of the two
motifs that were used to classify this domain (Bork 1993).
These motifs are characterised by the cysteine pattern and
numbered as such (with the number referring to which of
the 10 conserved cysteines is). The first: C2xxC3xC4, lies
towards the middle of the repeat and the second, C8C9xx
C10, lies towards the end of the repeat. These motifs are
conserved in the CCN proteins as can be seen in Fig. 1 but
with slight modifications. Both are extended with an extra
residue between C2 and C3 and two extra residues between
C9 and C10 (Bork 1993) except in CCN6 where 4 cysteine
residues are missing (numbers 2, 6, 8 and 9) (Bork 1993).
The structures of several different VWC domains are
known including those from collagen [PDB IU5M]
(O’Leary et al. 2004) determined by NMR and the chordin
family member crossveinless 2 (CV2) (from Drosophila)
[PDB 3BK3] (Zhang et al. 2008) which was determined by
X-ray crystallography. Both domains, as would be
expected, possess a highly similar structure. The domain,
shown in Fig. 2, forms an extended “boot-like” shape made
up of two roughly equal size sub domains- subdomain 1
(SD1) is more structured and comprises the N-terminal part
of the domain with a short two stranded anti-parallel β-
sheet followed by a 3 stranded anti-parallel β-sheet. The
triple sheet is supported by a disulphide bond between
strands 2 and 3, and a second disulphide bridge formed
between strand 2 and the first strand of the two-stranded
sheet. The second sub-domain (SD2) is far less structured
being comprised of random coil with no secondary
structure elements but is constrained by 3 disulphide
bridges into a novel fold that is reminiscent in fibronectin
(O'Leary et al. 2004; Zhang et al. 2008) and may possess
similar interactions with growth factors (O'Leary et al.
2004). An additional important feature is also present in the
Drosophila CV2 structure at the extreme N-terminal region
formed from the first 8 or so residues that has been called
the “clip” domain as it wraps around the BMP substrate like
a paperclip with several hydrogen bonds; although this clip
region is not seen in the VWC domain from chordin (Zhang
et al. 2008; O’Leary et al. 2004). In BMPs, TGF-β1 and the
related growth factors there are two binding epitopes that
have been recognised (Zhang et al. 2007), a “knuckle” and
“wrist” region that are crucial for receptor binding. There
are some results that suggest in the case of the VWC
repeats' antagonistic behaviour towards BMPs that they
interfere with the interactions between the “knuckle
epitope” and the BMP-receptor II (Keller et al. 2004;
O'Leary et al. 2004). Some of the biological effects of the
VWC domains may come about from the domain blocking
access to these epitopes and inhibiting receptor binding. In
the case of interaction between BMPs and a variety of
VWC domains it has become clear there are two main
modes of binding. Those that bind at the “wrist” epitope
involve mainly hydrophobic interactions and those that
bind at the “knuckle” epitope that have hydrophobic
interactions and the “clip” region that acts as an “affinity
enhancer” through a series of hydrogen bonds (Zhang et al.
2007; Zhang et al. 2008). In the structure of BMP2 bound
to Drosophila CV2, it was strong hydrophobic interactions
on a relatively small area of the face of SD1 and hydrogen
bonds from the clip region that were responsible for high
affinity binding (Zhang et al. 2008).
Models of the six CCN VWC domains were generated
using the CPH model server (Lund et al. 2002) and NMR
structure of the VWC-like domain from collagen IIA [PDB
IU5M] (O'Leary et al. 2004) as a template and can be seen
in Figs. 3, 4, 5 and 6. The only model that did not have all
10 cysteines visible, including those present in the two
conserved motifs (C2xxC3xC4; C8C9xxC10) was CCN2 that
was slightly truncated but this is due to the modelling
program rather than any significant differences in the CCN2
VWC domain. All of the modelled domains share the same
two sub-domain layout with a more structured sub-domain
at the N-terminal end and a fibronectin-like fold of random
coil supported by the disulphide bridges at the C-terminal
end (O'Leary et al. 2004; Zhang et al. 2008). Also like the
chordin structure [PDB 1U5M](O'Leary et al. 2004), they
do not possess the clip region that was seen in the CV2
structure [PDB 3BK3](Zhang et al. 2008). As the position
of this clip region in amino acid sequence is located in the
short linker region between the IGFBP and VWC domains
it is likely that it is not present in the CCN VWC domain.
In the case of the interactions between TGF-β and the
variety of BMPs that are known to bind CCN molecules it
is not possible to speculate on the exact nature of the
interaction or whereabouts on the VWC domain that this
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interaction takes place though the lack of space in the
sequence to form a “clip” segment would suggest that it
would bind the wrist epitope of the BMPs (Zhang et al.
2008). Furthermore, while CCN proteins closely resemble
each other in their arrangement a look at their electrostatic
surfaces, shown in Figs. 3, 4, 5 and 6, illustrates a wide
range of differences between them. CCN1 and to a lesser
extent CCN5 are primarily negatively charged on the front
face of the VWC domain whilst CCN4 is primarily
positively charged. The remaining molecules have a mix
of charges on their surface. The large differences in surface
charge may play a part in the different behaviours of CCN
family members or how they can arrange themselves with
either inter- or intra- molecular oligomerisation. A second
reason for the difference between the family members may
be in differences in the loop regions surrounding the
disulphide core as this method of substrate selectivity has
been observed in the disulphide rich conotoxins (Zhang et
al. 2007; Armishaw and Alewood 2005).
The thrombospondin type 1 (TSP) domain
The TSP domain is a short sequence (~55 residues) that is
found in 187 TSP proteins within the human genome and
numerous other eukaryotic organisms (Tucker 2004). There
is a large number of mostly extracellular matrix associated
proteins that possess a TSP domain and these include:
thrombospondins and spondins, papilin, extracellular ma-
trix ADAMTS, mindin and complement pathway proteins
(C6, C7, C8A, C8B, C9 and properdin) (Adams and Tucker
2000; Tucker 2004). The domain is named after the
thrombospondin family of angiogenic regulators. This family
members all share a common structure including a three
type I thrombospondin repeats (TSP domain), three epi-
dermal growth factor-like repeats (thrombospondin type -2
repeats) and seven aspartic acid rich repeats (thrombospon-
din type-3 repeats) (Tucker 2004; Lawler and Hynes 1986;
Iruela-Arispe et al. 2004; Karagiannis and Popel 2007).
From studies on thrombospondin and other TSP con-
taining proteins the domain seems to have 4 common
functions- a) cell attachment sites in signalling and
adhesion, b) regulation of angiogenesis, c) protein binding
sites for a range of growth factors and other ECM proteins
and d) glycosaminoglycan (GAG) binding sites (Chen et al.
2000). These functions obviously cover a wide range of
biological roles and necessitate a diverse array of binding
partners that can interact with the TSP domain. Many of
these have been identified and include key signalling
molecules such as collagen V (Takagi et al. 1993),
fibronectin (Sipes et al. 1993), CD36 (Asch et al. 1992),
TGF-B (Schultz-Cherry et al. 1995) and heparin (Guo et al.
1992) and a wide range of extracellular proteins.
The TSP domain in the CCN proteins is known to have a
strong role in adhesion and modulation of ECM proteins
(Planque and Perbal 2003) through interactions with the
lipoprotein- related receptor (Heng et al. 2006; de Winter et
al. 2008), binding to sulphated glycoconjugates (Holt et al.
1990) and interacting with several different integrins
(Kubota and Takigawa 2007).
Thrombospondin and related proteins are a well known
and potent family of angiogenic regulators (Folkman 1996;
Karagiannis and Popel 2007) as is the CCN family (Perbal
2004; Kubota and Takigawa 2007) and the TSP domain is
an important component of their angiogenic property. In
CCN proteins both the TSP domain and the CT domain
interact with VEGF- one of the key angiogenic growth
factors (Inoki et al. 2002). Whilst VEGF can be found in
several isoforms the TSP domain of CCN2 binds to the
heparin-binding VEGF165 isoform in an anti-angiogenic
mode of action, whilst the CT domain is involved in
interactions with both VEGF165 and VEGF121. The TSP
domain of other CCN proteins has been confirmed to have
an anti-angiogenic mode of action and indeed only an
isolated fragment of the TSP domain was needed to inhibit
proliferation and migration of HUVEC cells (Karagiannis
and Popel 2007; Tong and Brigstock 2006). This anti-
angiogenic effect can be removed by treating CCN2 with
matrix metalloproteases (MMPs) that are known to target
the spacer regions between the CCN modules (Ball et al.
1998; Inoki et al. 2002) suggesting that anti-angiogenic
effect comes about from the TSP binding to and sequester-
ing the VEGF165 away from its receptors and the MMP
cleavage frees the VEGF. Another small growth factor that
interacts with the TSP domain is TGF-β. In other
thrombospondins such as thrombospondin -1, this requires
an RFK tripeptide sequence found between the 1st and 2nd
TSP domains of the protein. However, the TSP-1 domains
in all of the CCN proteins lack this sequence so it may be
another module is involved with TGF-β binding (Tan et al.
2002) or a combination of the TSP domain working
synergistically with another of the TGF-β binding domains
such as the CT domain that contains a reversed KFR
tripeptide sequence (Kubota et al. 2006).
In addition to modulating angiogenesis through inter-
actions with VEGF the TSP domain may have other
biological functions mediated by integrin binding. Integrin
α6β1 is a key receptor for TSP and responsible for many of
the biological effects determined by the TSP domains
(Tong and Brigstock 2006). Both CCN1 and CCN2
promote adhesion of fibroblasts and vascular smooth
muscle cells through interactions with integrins and heparin
sulphated proteoglycans with which the TSP domain is
known to interact in support this hypothesis (Adams and
Tucker 2000). Signalling through integrin binding is
thought to be essential for the activity of the CCN family
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(Lau and Lam 1999) and hence the presence of TSP1
domain may be vital to function of these proteins. TSP
domains have also been shown to interact with TGF-β
(Adams and Tucker 2000) and interactions with TGB-β are
central to many of the roles that the CCN proteins play and
its possible that the interactions with TGF-β may be co-
ordinated by the TSP domain working in conjunction with
other domains of the CCN protein (Brigstock 1999; Lau
and Lam 1999; Brigstock 2003). Like other domains it is
possible that the TSP domain has some involvement in
cancers (Perbal 2006) and there have been some studies that
have linked CCN proteins with mutated or missing TSP
domains with colorectal and gastric carcinomas (Thorstensen
et al. 2001; Tanaka et al. 2002) as well as Wilm’s tumours
(Subramaniam et al. 2008).
The TSP domain in the CCN proteins contains the
motifs found in many other TSP repeats throughout the
eukaryotic genomes. As it is so common several TSP
domains have had their structures determined through a
combination of both X-ray crystallography and NMR.
These structures include: thrombospondin (Tan et al.
2002), malaria TRAP protein (Tossavainen et al. 2006)
and F-spondin (Paakkonen et al. 2006). Using the CPH
modelling server (Lund et al. 2002) the structures of
malaria TRAP protein [PDB ID 2BBX] (Tossavainen et
al. 2006) (for CCN 1, 3 and 5) or thrombospondin-1 [PDB
ID 1LSL] (Tan et al. 2002) (for CCN 2,4 and 6) were used
to construct models of the TSP domains for all six CCN
proteins. In each case the models were about 45 residues in
length and contained the same structural pattern as that of
the actual thrombospondin structures and are shown in
Figs. 3, 4, 5 and 6. The TSP domain is a small ~55 residue
domain comprised of a small 3-stranded anti-parallel β-
sheet (approximately 15 × 20 × 55Å) that is twisted slightly
into a right handed helical shape where the first strand is a
more irregular and resembles random coil but still main-
tains hydrogen bonds with the adjacent strand (Tan et al.
2002). There are 6 conserved cysteines that are all used in
inter-domain disulphide bridges and a conserved CSxTCG
motif, which can be seen in the CCN proteins in Fig. 1 and
the ribbon diagram in Fig. 2 (except in CCN3 that
substitutes the T for an S). The other important structural
feature of the TSP domains is the “CWR” layers. These are
an array of hydrogen bonds between residues that form the
faces of the β-strands and alongside the disulphide bonds
give rise to a ladder-like series of bonded amino acids. Each
layer is named from the amino acid that forms the hydrogen
bonds; cysteine (C), tryptophan (W) or arginine (R). These
layers in the other thrombospondin containing proteins
come about from a strongly conserved WxxWxxW motif
and a pair of well conserved arginines (Bork 1993; Tan et
al. 2002). The 3 conserved disulphide bonds present in each
TSP domain link the turns together at the top and bottom of
the sheet to stabilise the structure. The complete series of 3
disulphide bridges can only be seen in the model of CCN5
as the other models are slightly truncated due to the
limitations of structural homology modelling. But if the
models could be extended then all of the cysteines are con-
served in the protein sequence to form the correct sulphur-
sulphur bonds. Based on the pattern of these disulphide
bridges and the strands where the cysteines appear, Tan et
al (2002) broadly divided the TSP family into two broad
groups. In the models of the CCN TSP domains the
disulphide pattern would place the CCN domains in group
2 alongside F-Spondin, TRAP and the various proteins of
the complement system (Tan et al. 2002). However the
domains in the CCN family lack the tryptophan rich motif
(only possessing a single tryptophan residue) and only
having a single arginine residue leading to less CWR layers
(Figs. 3, 4, 5 and 6). The importance of the CWR layers
beyond maintaining the structure of the domain is unknown
as the biologically active section has been determined to be
a short section of ~12 residues that makes up the first strand
and part of the second (Karagiannis and Popel 2007; Tong
and Brigstock 2006). These short peptides have been
shown to be biologically active for CCN1–3, 5 and 6
(Karagiannis and Popel 2007). In addition to the short
biologically active section of strands 1 and 2 there is another
unifying feature of the TSP domain shared between all 6
members of the CCN family. This is a groove running across
the face of the molecule that is lined with basic residues and
is large enough to accommodate 2 heparin molecules. The
basic residues would be available to form strong electrostatic
bonds with negatively charged sulphur groups on sulphated
heparin molecules. As this is conserved in all six of the
models it might suggest that all the CCN proteins use the
TSP domain in a similar manner for binding to heparin or
sulphated proteoglycans to modulate cell adhesion and ECM
composition in a similar manner to thrombospondin and
other TSP containing proteins (Tan et al. 2002).
The cysteine knot C-terminal (CT) domain
The CT domain is named after the ‘cysteine knot’ motif
that it contains (Bork 1993). Cysteine knots are common to
many other proteins both large mosaic extracellular matrix
proteins such as Drosophila slit protein, the von Willebrand
factor, several mucins, Norrie disease protein and the TGF-
β family of small growth factors (Bork 1993; McDonald
and Hendrickson 1993). This family includes TGF, VEGF,
BMPs, nerve growth factor (NGF), platelet derived growth
factor (PDGF) and the Norrie disease protein (Bork 1993;
McDonald and Hendrickson 1993).
Many of the biological functions of the small growth
factors come about through interactions with heparin and
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heparin sulphate proteoglycans (HSPGs) (Lyon et al. 1997;
Rider 2006). While the TSP domain is also thought to bind
heparin or HSPGs it has been confirmed that the CT
domain can do the same, porcine CCN2 fragments
consisting of just the ~10 kDa CT domain bind heparin
strongly and are biologically active (Brigstock et al. 1997).
In the CCN proteins the interactions with heparin and
HSPGs are likely connected to many of the important roles
in controlling and manipulating adhesion processes and the
composition of the ECM alongside. It is well known that
heparin is an important modulator in adhesion processes
and in forming and controlling the extracellular matrix.
Interactions between the CT domain and heparin are not the
only method through which CCN molecules can control
adhesion. Interactions between the CT domain and Fibulin
1C (Perbal et al. 1999), and several different integrins such
as αVβ5, αvβ3, αmβ2 and α5β1 (Grzeszkiewicz et al.
2001; Gao and Brigstock 2004; Gao and Brigstock 2006)
have been observed and that the constructs containing only
the CT domain can bring about cell adhesion (Ball et al.
2003). The large number of integrins that interact with the
CT domain do so through several different binding sites
although in the CCN proteins none of these use the
common RGD tripeptide - integrin binding motif seen in
many other proteins. Although interestingly in CCN2
integrin α5β1 binds to a DGR motif, possibly a reverse
integrin binding site (Gao and Brigstock 2006).
A second role for the CT domain in regulating mitogenic
effects cell differentiation and other mitogenic processes
may come about through interactions with cell differentia-
tion molecule Notch 1 (Sakamoto et al. 2002) and the
apoptosis inducing integrin α6β1 (Todorovicc et al. 2005)
and artifical truncates of the CT domain have been seen to
promote and control these effects (Brigstock et al. 1997). In
addition to its mitogenic effects the isolated CT domain of
CCN3 has been seen to possess a anti-proliferative function
preventing both proliferation and differentiation of mesen-
chymal stem cells (Katsuki et al. 2008) and was recently
reported to contain sequences that are involved in the
nuclear addressing of CCN variants lacking the signal
peptide (Planque et al. 2006).
While the sheer number of pathways that can be
regulated and controlled by HSPGs may lead many to
consider HSPGs and integrins as the “functional receptors
for the CCN family” (Leask and Abraham 2006). There are
additional functions independent of the integrin/HSPG
pathways. Recombinant constructs of the CT domain can
modulate the Wnt pathway through interactions with the
LDL receptor protein 6 (LRP6) (Mercurio et al. 2004;
Latinkic et al. 2003). Though as the Wnt relies on integrins
to recruit some the associated proteins it is possible that the
modulation of the Wnt pathway comes about from
convergent actions of the CT domain on Wnt complex
and integrins (Lau and Lam 1999; Marsden and DeSimone
2001; Mercurio et al. 2004). All of these roles suggest that
the part played by the CT domain in CCN function is
highly important and as yet still not fully understood.
The cysteine knot containing ECM proteins and small
growth factors all share a cysteine knot motif though the
range of molecules possessing this motif exhibit significant
sequence variation outside of the core knot fold (McDonald
and Hendrickson 1993). A cysteine knot is an 8 residue ring
based around a two-stranded anti-parallel β-sheet (with
each strand at least 4 residues long) linked by 2 disulphide
bonds to complete the ring and a third bond through the
centre of the “knot” (Fig. 2). In some cases there is a short
alpha-helix on the opposite side of the cysteine knot rather
than two β-strands (McDonald and Hendrickson 1993;
Schlunegger and Grutter 1993; Rider 2006; Isaacs 1995).
Many of the growth factors are found naturally as dimers
linked through disulphides. In the case of both NGF and
TGF-β the disulphide that threads through the centre of the
knot is inter-chain and it is a different cysteine that is
responsible for the dimer formation, whilst in platelet
derived growth factor (PDGF) it is the cysteine passing
through the centre of the knot that forms an intra-chain
disulphide bond to complete the dimer. It is unknown in the
CCN proteins which of these arrangements the CT domain
follows although it is the CT domain responsible for
forming CCN dimers (Brigstock 1999; Perbal et al. 1999).
Using the CT domain of CCN proteins both homo- and
hetero-dimers can be formed as the CT domain of CCN3
has been seen to interact with CCN2 in GST pull-down
assays (Perbal et al. 1999). It is possible that this dimeri-
sation about the CT domains is followed by oligomerisa-
tion about the VWC domain to produce the CCN
oligomers that have been observed (Planque and Perbal
2003).
The sequence diversity outside of the core cysteine knot
motif made modelling the CT domains of the CCN proteins
more difficult. The CPH model server (Lund et al. 2002)
was unable to construct models of the CT domain for any
of the CCN molecules. Instead the Phyre homology and
recognition server was used (Kelley et al. 2000; Bennett-
Lovsey et al. 2008). Even then the Phyre server was only
able to build partial models for CCN1-3. These partial
models contained ~50 residues out of the ~80 residue
domain though this did include the cysteine knot. Due to
sequence variation a different template had to be used in
each case. The BMP7 was the template structure for CCN1
[PDB ID 1LXI] (Greenwald et al. 2003), the TGF-β3
structure [PDB ID 1KTZ] (Hart et al. 2002) for CCN2 and
TGF-β1 as a template [PDB ID 1KLA] (Hinck et al. 1996)
for CCN3. The models can be viewed in Figs. 3, 4 and 5. In
the visible sections of the models the cysteine knot can be
seen formed by a two stranded anti-parallel β-sheet with the
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two disulphides that connect the β-strands and close the ring.
A fifth cysteine protruding through the ring becomes
available for a third disulphide bond formation. Though
without a complete structure it is still unknown whether this
third disulphide will be intra-molecular within the CT
domain or inter-molecular and bind to other cysteine knot
containing growth factors or form a dimer with other CCN
molecules (Perbal et al. 1999). The heparin binding site in
most growth factors is isolated at the tips of loops between
the β-sheets and has 4 basic residues on the first sheet and a
single Arg/Lys residue on the tip of loop on the second
sheet (Lyon et al. 1997; Rider 2006). All of the CCN
proteins except for CCN5 (that lacks the CT domain)
possess a high number of basic residues at the N-terminal
of the CT domain that follow the general heparin binding
pattern of xBBxBx (where B is a basic residue and x is
usually not charged) (Cardin and Weintraub 1989). How-
ever the N-terminal residues including the heparin binding
basic region and the loops at the end of the β-strands were
unable to be modelled for any of the CCNs. While all of the
CT domains seem to have a similar arrangement, the
electrostatic surfaces of each appear to show some differ-
ences and this coupled with a fairly diverse amino acid
sequence (apart from the conserved cysteines) may account
for the wide range of ligands and binding partners that have
been found for the CT domain. However, many of these
differences may only become apparent with the availability
of experimentally determined structures.
The CT domain with its heparin (Bork 1993; Brigstock
et al. 1997), growth factor-like(Bork 1993), integrin and
Wnt pathway binding (Mercurio et al. 2004) seems like it
could be the major force for direct protein-protein inter-
actions and the availability or presence of the other domains
modulate the results of these interactions. The CT domain’s
involvement with integrin and HSPG mediated pathways
and mitogenic effects has been seen and biologically active
truncates of the CT domain alone are enough to produce
these effects and in CCN3 inhibit growth (Brigstock et al.
1997; Bleau et al 2007). This makes the CT domain one of
the most important domains for CCN protein behaviour as
it seems to govern many crucial aspects of CCN biology
including dimerisation and also begs the question- “how
does CCN5 manage many of the same effects of the other
family members without the CT domain?”
Conclusions
CCN proteins all share the similar basic modular structure
and a high degree of amino acid sequence similarity and
play a part in many cellular functions. However the sheer
number of functions and often opposing functions of
different CCN molecules make it unlikely that these
functions are wholly based upon the action of individual
domains, but rather on a cumulative effect between multiple
domains and receptors (Brigstock 1999; Lau and Lam
1999; Perbal 2001b). This is supported by the work
performed by Kubota el al (Kubota et al. 2006) where
many effects could be elicited by individual domains, in
some cases elicited by all 4 domains, but other effects
required the full length protein or a mixture of individual
domains (Kubota et al. 2006).
The use of a small library of discrete domains acting as a
building blocks to create much larger complex multifunc-
tional extracellular associated proteins is a common
occurrence in many eukaryotes (Hohenester and Engel
2002) and places the CCN proteins in the same category as
many other multifunctional matrix associated proteins.
However while the knowledge of which domains are
present is useful it does not offer a straightforward
explanation into how the modular structure of these
proteins is able to control or regulate the complex
behaviour of these proteins. Evidence of internal protein
regulation by interactions between the domains is hard to
obtain but the change in biological activity of truncates
missing various domains would certainly support this idea.
The flexible nature of the full length molecule with the long
central linker region and shorter inter-domain linkers would
also allow a great deal of flexibility within the CCN
molecules. Also the nature of multiple domains binding to
the same target, such as both domains III and IV binding to
VEGF (Inoki et al. 2002) may indicate some synergy
between domains in substrate binding, or an altering of
subtle biological signals depending on the various mix of
domains involved. In addition, the role of the CT as a
dimerisation domain (Bork 1993) and the suspected role of
the VWC domain in forming larger higher order oligomers
may result in some of the functions being modulated by
multiple CCN proteins in a larger complex working
together (Bork 1993; Brigstock 1999; Perbal et al. 1999).
In an oligomer multiple domains may act together upon
substrate binding to mimic the way the VWC or TSP
repeats function in other large multi-domain proteins
(Adams and Tucker 2000; Mancuso et al. 1989). This is
further complicated by the ability of domain IV to form
heterodimers between differing CCN family members
adding an additional layer of complexity as it is possible
that some effects come about through a cumulative effect of
different CCN molecules in a larger complex (Perbal et al.
1999).
The varied and often conflicting behaviour of the CCN
family members may not just be down to subtle differences
in structure but to other factors like proteolytic processing,
control of gene expression or even the organ or spatial
locations in the cell that each are expressed. This may
suggest that time dependant expression of the CCN
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proteins, such as CCN1 and CCN2 being immediate early
genes whilst CCN3 is not (Bradham et al. 1991; O’Brien
and Lau 1992; Joliot et al. 1992) is an important functional
level of regulation. The protease cleavage of the linker
regions leads to differing functions due to the loss of
certain domains in biologically isolated truncates (Tong
and Brigstock 2006; Brigstock 1999) such as CCN2 losing
its anti-angiogenic effects after treatment with certain
MMPs (Hashimoto et al. 2002). The use of different
expression regulatory systems and tissue specificities could
go some way to explaining the conflicting range of func-
tions that can be found amongst the CCN molecules despite
the high degree of similarity at the amino acid sequence
level (Brigstock 1999; Perbal 2001a; Perbal 2004) .
While approximate structures of each domain could be
modelled based on their similarity (homology) with known
structures, it is likely that the CCN proteins have some
features that help explain their specificity and possibly a
route through which they regulate themselves through inter-
domain interactions. These could take place either through
flexibility about the hinge regions or additional loops but
these are features that would require structural determina-
tion of the proteins in question to confirm. Linker regions
acting as “hinges” allowing large domain movements have
been shown to be involved in modulation of activity of
other mosaic proteins (Dobson 1990) and the nature of the
linker regions between domains of large ECM proteins, be
they helical or elongated, may also play a role (Arai et al.
2004). The ability of linker regions to be used as means of
inter-domain communication in large molecules may also
prove important in given the large variation in sequence and
length present in the CCN protein family (Bork 1993;
Brigstock 1999; Gokhale and Khosla 2000). The suscepti-
bility of the linker to proteolytic cleavage and biologically
active nature of many truncated CCN constructs may lead
to another layer of physiological control of CCN function
(Bork 1993; Brigstock et al. 1997; Ball et al. 1998).
However the flexible nature of the linkers means that they
can not be modelled. Hence it is hard to speculate on the
effect that differences in the linkers will have.
The differences in sequence can lead to large variations
in surface charge and amino acid composition and currently
unknown active sites whilst still retaining the same core
shape. The nature of the long hinge region and the observed
flexible natures of the VWC and TSP domains from their
related structures (Tan et al. 2002; O'Leary et al. 2004) may
also allow the N and C terminal of the CCN proteins to
interact with each other as suggested by Perbal (Perbal
2001b). The determination of the structure of each domain;
either individually or full length protein is necessary in
order to answer some of the key questions about the CCN
family of proteins by correlating structure to function
(Perbal 2001a).
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